Antibodies and methods of use thereof

US10836830B2 · kind B2 · utility

Assignees

• Agenus Inc. · US
• Memorial Sloan Kettering Cancer Center · US
• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

• Nicholas Stuart Wilson · Melbourne, AU
• Jeremy Dale Waight · Everett, US
• Gerd Ritter · New York, US
• David Schaer · Mamaroneck, US
• Daniel Hirschhorn-Cymerman · New York, US
• Taha Merghoub · New York, US
• Ekaterina V. Breous-Nystrom · Basel, CH
• Volker Seibert · Lörrach, DE
• Takemasa TSUJI · Williamsville, US
• Olivier Leger · Bonneville, FR
• Dennis John Underwood · Brookline, US
• Marc van Dijk · Bosch en Duin, NL

Key dates

• Filing date: Jun 19, 2020
• Grant date: Nov 17, 2020
• Expiry date: Jun 19, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.